‌

US Patent 11963952 Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer

Patent 11963952 was granted and assigned to Aragon Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Aragon Pharmaceuticals

0

Current Assignee

Aragon Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Margaret K. Yu0

Date of Patent

April 23, 2024

0

Patent Application Number

181682040

Date Filed

February 13, 2023

0

Patent Citations

US Patent 9987261 Substituted diazaspiroalkanes as androgen receptor modulators

0

US Patent 8445507 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

0

US Patent 8802689 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

0

US Patent 9388159 Substituted diazaspiroalkanes as androgen receptor modulators

0

Patent Primary Examiner

0

Patent abstract

Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11963952 Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool